Skip to Content
Merck

Key Documents

View All Documentation

T2705

Topotecan hydrochloride hydrate

≥98% (HPLC and enzymatic), powder, topoisomerase I inhibitor

Synonym(s):

9-[(dimethylamino)methyl]-10-hydroxy-(20S)-camptothecin hydrochloride hydrate, NSC-609669 hydrochloride hydrate, SKF-104864A hydrochloride hydrate, hycamptamine hydrochloride hydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C23H23N3O5 · xHCl · yH2O
CAS Number:
123948-87-8
Molecular Weight:
421.45 (anhydrous free base basis)
UNSPSC Code:
12352200
PubChem Substance ID:
329826724
NACRES:
NA.77
MDL number:
MFCD00870670
Assay:
≥98% (HPLC and enzymatic)
Form:
powder
Quality level:
100
Storage condition:
desiccated, protect from light
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Topotecan hydrochloride hydrate, ≥98% (HPLC and enzymatic)

Quality Level

100

assay

≥98% (HPLC and enzymatic)

form

powder

storage condition

desiccated, protect from light

color

yellow

solubility

DMSO: ≥20 mg/mL

originator

GlaxoSmithKline

storage temp.

−20°C

SMILES string

[n]21c(cc5c([c]2=O)COC(=O)[C@]5(O)CC)c3nc4c(cc3C1)c(c(cc4)O)CN(C)C

InChI

1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1

InChI key

UCFGDBYHRUNTLO-QHCPKHFHSA-N

Gene Information

human ... TOP1MT(116447)

Application

Topotecan has been used as a positive control for the identification and analysis of HIF-1α and VEGF inhibitors in human glioma cells under hypoxic conditions1. It has also been used for in vitro apoptosis assays in PA317 cells2.

Biochem/physiol Actions

Topotecan is a topoisomerase I inhibitor and an apoptosis inducer. It is a potent antineoplastic agent.

Features and Benefits

This compound is a featured product for ADME Tox and Apoptosis research. Discover more featured ADME Tox and Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

This product is soluble in water, however, the concentration has not been determined. Various sources state this chemical can be solubilized in water at greater than 1 mg/mL.
Topotecan hydrochloride hydrate is soluble in DMSO at a concentration that is greater than or equal to 20 mg/ml.

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Muta. 1B - Repr. 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ian F King et al.
Nature, 501(7465), 58-62 (2013-09-03)
Topoisomerases are expressed throughout the developing and adult brain and are mutated in some individuals with autism spectrum disorder (ASD). However, how topoisomerases are mechanistically connected to ASD is unknown. Here we find that topotecan, a topoisomerase 1 (TOP1) inhibitor
ChunLei Li et al.
International journal of pharmaceutics, 443(1-2), 17-25 (2013-01-16)
Repeated injection of pegylated liposomes could elicit the disappearance of long-circulating characteristic, referred to as "accelerated blood clearance phenomenon." ABC phenomenon typically occurs when entrapped drugs are not cytotoxic, but recently it was reported that multiple doses of pegylated liposomal
Kaleem Ashraf et al.
Pediatric blood & cancer, 60(10), 1636-1641 (2013-05-08)
Reports of responses and toxicities of salvage therapies for relapsed neuroblastoma are rare and often confounded by effects of additional treatments. Our objective was to describe the outcomes and toxicities for a topotecan and cyclophosphamide (TOPO/CTX) regimen for first relapse
View All Related Papers